Ensign Peak Advisors, Inc Kiniksa Pharmaceuticals, Ltd. Transaction History

Ensign Peak Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$11.42 - $17.05 $129,160 - $192,835	-11,310 Reduced 14.55%	66,443 $995,000
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $263,119 - $361,520	26,959 Added 53.08%	77,753 $998,000
Q2 2022 Aug 12, 2022	SELL	$7.6 - $11.41 $14,789 - $22,203	-1,946 Reduced 3.69%	50,794 $492,000
Q4 2021 Feb 11, 2022	SELL	$10.39 - $15.15 $218,948 - $319,255	-21,073 Reduced 28.55%	52,740 $621,000
Q3 2021 Nov 12, 2021	BUY	$11.39 - $16.23 $235,636 - $335,766	20,688 Added 38.94%	73,813 $841,000
Q4 2020 Feb 12, 2021	BUY	$14.8 - $21.15 $398,356 - $569,273	26,916 Added 102.7%	53,125 $939,000
Q3 2020 Nov 12, 2020	BUY	$15.21 - $25.53 $271,604 - $455,889	17,857 Added 213.81%	26,209 $402,000
Q2 2020 Aug 12, 2020	BUY	$15.08 - $26.0 $125,948 - $217,152	8,352 New	8,352 $213,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.